Anti-ZFYVE27 antibody (ab61285)

Overview

• Product name
  Anti-ZFYVE27 antibody
  See all ZFYVE27 primary antibodies
• Description
  Rabbit polyclonal to ZFYVE27
• Tested applications
  Suitable for: WBmore details
• Species reactivity
  Reacts with: Human
  Predicted to work with: Mouse, Rat, Rabbit, Horse, Chicken, Guinea pig, Cow, Cat, Dog
• Immunogen

  Synthetic peptide corresponding to an internal sequence within amino acids 253-302 of Human ZFYVE27 GKDGLMDSTP ALTPTESLSS QDLTPGSVEE AEEAEPDEEF KDAIEETHLV

  Run BLAST with Run BLAST with
• Positive control
  • Jurkat membrane lysate

Properties

• Form
  Liquid
• Storage instructions
  Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
• Storage buffer
  Preservative: None
  Constituents: 2% Sucrose, PBS
• Concentration information loading...
• Purity
  Protein A purified
• Clonality
  Polyclonal
• Isotype
  IgG
• Research areas
  • Neuroscience
  • Neurology process
  • Neurodegenerative disease
  • Other

  • Neuroscience
  • Neurology process
  • Neurogenesis

Associated products

• Compatible Secondaries
  • Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077)
  • Goat Anti-Rabbit IgG H&L (HRP) (ab205718)
• Positive Controls
  • Jurkat membrane extract lysate (ab30130)

Applications

Target

• Function
  Functions as an upstream inhibitor of RAB11, regulating directional protein transport to the forming neurites. Involved in nerve growth factor-induced neurite formation. May have a more general role in cell projections formation.
• Involvement in disease
  Defects in ZFYVE27 are the cause of spastic paraplegia autosomal dominant type 33 (SPG33) [MIM:610244]. Spastic paraplegia is a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. Note=According to PubMed:18606302, the properties of the variant Val-191 and its frequency in some populations raise doubts on the implication of that gene in the disease.
• Sequence similarities
  Contains 1 FYVE-type zinc finger.
• Post-translational
  modifications
  Phosphorylated. Phosphorylation is induced by NGF through the MAPK/ERK pathway and modulates interaction with RAB11A.
• Cellular localization
  Recycling endosome membrane. Endoplasmic reticulum membrane. Cell projection > growth cone membrane. Cell membrane. Localizes at both dendrites and axons.

• Target information above from: UniProt accession Q5T4F4 The UniProt Consortium
  The Universal Protein Resource (UniProt) in 2010
  Nucleic Acids Res. 38:D142-D148 (2010) .

  Information by UniProt
• Database links
  • Entrez Gene: 486825 Dog
  • Entrez Gene: 118813 Human
  • Entrez Gene: 319740 Mouse
  • Entrez Gene: 309376 Rat
  • Omim: 610243 Human
  • SwissProt: Q5T4F4 Human
  • SwissProt: Q3TXX3 Mouse
  • SwissProt: Q6P7B7 Rat

  • Unigene: 523194 Human
  • Unigene: 287359 Mouse
  • Unigene: 470071 Mouse
  • Unigene: 99939 Rat

  see all
• Alternative names
  • Protrudin antibody
  • RP11 459F3.2 antibody
  • SPG33 antibody

  • ZFY27_HUMAN antibody
  • ZFYVE27 antibody
  • zinc finger FYVE domain containing 27 antibody
  • Zinc finger FYVE domain containing protein 27 antibody
  • Zinc finger FYVE domain-containing protein 27 antibody

  see all

Protocols

• Western blot protocols